➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 5,008,388

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,008,388
Title: Process for preparation of a new hemin complex
Abstract:The present invention relates to a method for the preparation of a new, physiologically active, water-soluble complex compound, hemin arginate or hemin lysinate. According to the invention crystalline hemin and one of the amino acids L-arginine or L-lysine, in a molar proportion of 1:3, are allowed to react at room temperature under vigorous stirring for 10 to 15 hours in a solvent mixture of acetone and water in a ratio of 300:20 v/v. The hemin arginate or hemin lysinate thus formed is a powdery, stable compound suitable for use as raw material in tablets or capsules or as dry substance for preparation of injections for treatment of various types of anemia, including iron deficiency anemia and anemias and diseases associated with defects in heme synthesis.
Inventor(s): Ingberg; Grels D. (Ekenas, FI), Penttila; Ritva L. A. (Helsinki, FI), Tokola; Reino O. (Helsinki, FI), Tenhunen; Raimo (Helsinki, FI)
Assignee: Huhtamaki Oy (Turku, FI)
Application Number:06/803,630
Patent Claims:see list of patent claims

Details for Patent 5,008,388

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Recordati Rare Diseases, Inc. PANHEMATIN hemin POWDER, FOR SOLUTION 101246 1 1983-07-20   Start Trial Huhtamaki Oy (Turku, FI) 2008-04-16 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.